Dr. Reddy’s signs voluntary licensing agreement with Gilead …
WEB15 hours ago · HYDERABAD, India, October 02, 2024--Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with ...
WEB13 hours ago · Apart from Dr Reddy’s Labs and Hetero, Emcure, Eva Pharma, Ferozsons Laboratories Ltd and Mylan too have inked pacts with Gilead for the first-in-class HIV-1 capsid inhibitor that was launched ...
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug
WEB14 hours ago · Hyderabad-based Hetero and Dr Reddy’s Laboratories have signed a non-exclusive, royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC to manufacture and distribute lenacapavir, a breakthrough HIV treatment drug, in 120 primarily low- and lower-middle-income countries (LMICs ...
Dr Reddy’s signs licensing pact with Gilead Sciences to …
WEB15 hours ago · Business News Live Ashneer Grover Diffusion Engineers IPO Allotment Status Bank Holidays in Octonber Gold Price Today. Dr Reddy’s enters pact with Gilead Sciences to manufacture, sell HIV drug ...
Dr. Reddy’s signs voluntary licensing agreement with Gilead …
WEB1 day ago · Dr. Reddy’s has been granted a non-exclusive voluntary licence to manufacture Lenacapavir and market it in 120 countries, for the current approved indication of HIV treatment in heavily ...
Dr. Reddy’s signs voluntary licensing agreement with Gilead …
WEB15 hours ago · HYDERABAD, India--(BUSINESS WIRE)--Oct. 2, 2024-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the ...
2024-10-02 | Dr. Reddy's signs voluntary licensing agreement with ...
WEB1 day ago · Dr. Reddy’s has been granted a non-exclusive voluntary licence to manufacture Lenacapavir and market it in 120 countries, for the current approved indication of HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. Dr. Reddy's will be responsible for technology transfer at its manufacturing ...
Dr Reddy's completes acquisition of UK co Haleon's non-US …
WEBHyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine replacement therapy (NRT) business for GBP 458 million. The deal ...
Dr. Reddy’s becomes first Indian pharma company to debut on …
WEBDec 14, 2023 · Dr. Reddy’s has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023.
Dr. Reddy's Laboratories Announces the Appointment of Milan …
WEBHYDERABAD, India, May 28, 2024--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.